Intrexon | XON - Собственный капитал и резервы





Собственный капитал и резервы Изменить Дата
Agenus USD -271.11M 3.03M 2025-12
Alaunos Therapeutics USD 2.8M 858K 2025-09
Amgen USD 8.66B 961M 2025-12
Anika Therapeutics USD 143.46M 3.34M 2025-12
Arrowhead Research USD 568.42M 102.37M 2025-12
AstraZeneca USD 48.67B 2.78B 2025-12
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Gilead Sciences USD 22.62B 1.16B 2025-12
GlaxoSmithKline GBP 16.38B 229M 2025-12
Heron Therapeutics USD 13.28M 1.6M 2025-12
Incyte USD 5.17B 516.28M 2025-12
Intrexon USD 43.17M 75.33M 2024-06
Karyopharm Therapeutics USD -269.26M 30.33M 2025-09
Ligand Pharmaceuticals USD 1.02B 67.04M 2025-12
MacroGenics USD 55.59M 11.41M 2025-12
MannKind USD -51.02M 6.47M 2025-12
Merck USD 51.85B 2.79B 2025-09
Novartis USD 46.13B 1.38B 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Roche Holding CHF 33.8B 758M 2025-12
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Thermo Fisher Scientific USD 53.54B 2.38B 2025-12
Veracyte USD 1.26B 36.61M 2025-09
Xencor USD 635.59M 10.27M 2025-12